- Reaction score
- 678
0.035 mg of ethinyl estradiol and 2 mg of cyproterone acetate (EE35-CPA), for hormonal and clinical parameters of 66 patients with polycystic ovary. syndrome (PCOS). While taking the pill, there was a significant decrease in the ratio of LH / FSH and androgens of the adrenal glands and ovaries, as well as a significant increase in sex hormone binding globulin (SHBG). A progressive decrease in total androgenic activity explains the clinical results that were obtained: on the 36th cycle of therapy, acne disappeared in 100% of cases, seborrhea in 76.4% and hirsutism in 75%. Our results highlight the need for continuous administration without interrupting the administration of pills with CPA in patients with clinical hyperandrogenic symptoms.
https://www.ncbi.nlm.nih.gov/m/pubmed/2150631/
https://www.ncbi.nlm.nih.gov/m/pubmed/2150631/